Samuel K. Ackerman
Chief Executive Officer at Cyclis Pharmaceuticals, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Chyi-Shan Suen | M | - |
Vitex Systems, Inc.
| 15 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| John R. Barr | M | 67 |
V.I. Technologies, Inc.
 V.I. Technologies, Inc. BiotechnologyHealth Technology Vitex is a Delaware Corporation incorporated in 1995. Vitex’s scientific and clinical programs originated in anti-infective technologies designed to prevent the spread of infectious disease by blood transfusions. In March of 2005, Vitex merged with Panacos Pharmaceuticals, a private company developing HIV therapeutics with novel mechanisms of action. The merger with Panacos immediately expanded the Vitex pipeline into novel, high value therapeutics. The Panacos team that joined Vitex is recognized for fundamental contributions to HIV biology and drug development | 8 years |
| Peyton J. Marshall | M | 69 | 2 years | |
| Frederick Schmid | M | 67 | 2 years | |
| David Tendler | M | - |
V.I. Technologies, Inc.
V.I. Technologies, Inc. BiotechnologyHealth Technology Vitex is a Delaware Corporation incorporated in 1995. Vitex’s scientific and clinical programs originated in anti-infective technologies designed to prevent the spread of infectious disease by blood transfusions. In March of 2005, Vitex merged with Panacos Pharmaceuticals, a private company developing HIV therapeutics with novel mechanisms of action. The merger with Panacos immediately expanded the Vitex pipeline into novel, high value therapeutics. The Panacos team that joined Vitex is recognized for fundamental contributions to HIV biology and drug development | - |
| Herb H. Hooper | M | 60 |
V.I. Technologies, Inc.
V.I. Technologies, Inc. BiotechnologyHealth Technology Vitex is a Delaware Corporation incorporated in 1995. Vitex’s scientific and clinical programs originated in anti-infective technologies designed to prevent the spread of infectious disease by blood transfusions. In March of 2005, Vitex merged with Panacos Pharmaceuticals, a private company developing HIV therapeutics with novel mechanisms of action. The merger with Panacos immediately expanded the Vitex pipeline into novel, high value therapeutics. The Panacos team that joined Vitex is recognized for fundamental contributions to HIV biology and drug development | - |
| Doros Platika | M | - |
V.I. Technologies, Inc.
V.I. Technologies, Inc. BiotechnologyHealth Technology Vitex is a Delaware Corporation incorporated in 1995. Vitex’s scientific and clinical programs originated in anti-infective technologies designed to prevent the spread of infectious disease by blood transfusions. In March of 2005, Vitex merged with Panacos Pharmaceuticals, a private company developing HIV therapeutics with novel mechanisms of action. The merger with Panacos immediately expanded the Vitex pipeline into novel, high value therapeutics. The Panacos team that joined Vitex is recognized for fundamental contributions to HIV biology and drug development | - |
| John Richards | M | 67 | 3 years | |
| Eric Linsley | M | 62 |
V.I. Technologies, Inc.
V.I. Technologies, Inc. BiotechnologyHealth Technology Vitex is a Delaware Corporation incorporated in 1995. Vitex’s scientific and clinical programs originated in anti-infective technologies designed to prevent the spread of infectious disease by blood transfusions. In March of 2005, Vitex merged with Panacos Pharmaceuticals, a private company developing HIV therapeutics with novel mechanisms of action. The merger with Panacos immediately expanded the Vitex pipeline into novel, high value therapeutics. The Panacos team that joined Vitex is recognized for fundamental contributions to HIV biology and drug development | - |
| R. Fletcher | M | 78 |
V.I. Technologies, Inc.
V.I. Technologies, Inc. BiotechnologyHealth Technology Vitex is a Delaware Corporation incorporated in 1995. Vitex’s scientific and clinical programs originated in anti-infective technologies designed to prevent the spread of infectious disease by blood transfusions. In March of 2005, Vitex merged with Panacos Pharmaceuticals, a private company developing HIV therapeutics with novel mechanisms of action. The merger with Panacos immediately expanded the Vitex pipeline into novel, high value therapeutics. The Panacos team that joined Vitex is recognized for fundamental contributions to HIV biology and drug development | - |
| John R. Chapman | M | 70 |
V.I. Technologies, Inc.
V.I. Technologies, Inc. BiotechnologyHealth Technology Vitex is a Delaware Corporation incorporated in 1995. Vitex’s scientific and clinical programs originated in anti-infective technologies designed to prevent the spread of infectious disease by blood transfusions. In March of 2005, Vitex merged with Panacos Pharmaceuticals, a private company developing HIV therapeutics with novel mechanisms of action. The merger with Panacos immediately expanded the Vitex pipeline into novel, high value therapeutics. The Panacos team that joined Vitex is recognized for fundamental contributions to HIV biology and drug development | 6 years |
| Kurt J. W. Andrews | M | 54 |
V.I. Technologies, Inc.
V.I. Technologies, Inc. BiotechnologyHealth Technology Vitex is a Delaware Corporation incorporated in 1995. Vitex’s scientific and clinical programs originated in anti-infective technologies designed to prevent the spread of infectious disease by blood transfusions. In March of 2005, Vitex merged with Panacos Pharmaceuticals, a private company developing HIV therapeutics with novel mechanisms of action. The merger with Panacos immediately expanded the Vitex pipeline into novel, high value therapeutics. The Panacos team that joined Vitex is recognized for fundamental contributions to HIV biology and drug development | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 12 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Samuel K. Ackerman
- Personal Network
